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Abstract: Epilepsy is one of the most common neurologic disorders, affecting about 50 million 
people around the world. It is recognized that around 50% of patients with newly diagnosed 
epilepsy become seizure-free with the first drug treatment, so the choice of first antiepileptic drug 
is crucial. This paper provides a comprehensive overview of zonisamide as monotherapy for 
partial seizures, with special attention to the possibility of a once-daily regimen. The available 
data suggest that zonisamide is an effective and well tolerated option as monotherapy. Once-
daily dosing is indicated, considering the long plasma half-life and linear pharmacokinetics of 
the drug. Zonisamide 300 mg was shown to be noninferior to carbamazepine 600 mg in terms of 
efficacy and safety, but even lower doses may be effective. Finally, the broad spectrum of efficacy 
in different seizure types, the low drug interaction potential, and the possibility of weight loss 
make zonisamide a preferred option in many epilepsy practices. Further data on monotherapy, 
especially in special populations, such as women of childbearing potential, are needed.
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Introduction
Epilepsy is one of the most common neurologic disorders, affecting about 50 million 
people worldwide.1 The World Health Organization reports that the overall health 
burden due to epilepsy accounts for 0.5% of the global burden of the disease, with total 
annual costs of approximately 15.5 billion Euros in Europe,2 and 9.5 billion dollars in 
the US.3 Over 40 types of epilepsies are known, and they fall into two main categories, 
ie, partial onset (also known as focal or localization-related)4 epilepsies and generalized 
onset epilepsies, the former accounting for about 60% of all adult epilepsy.5
In general terms, about 50% of patients with newly diagnosed epilepsy are expected 
to become seizure-free with the first treatment.6 Another 20% can reach long-lasting 
and complete seizure control with a second drug or on dual therapy.7 Therefore, it is 
evident that choice of the first antiepileptic drug is critical. Moreover, monotherapy 
has a number of advantages in terms of good patient compliance, a low risk of drug 
interactions, and potential cost savings.8
A number of treatment guidelines have been published giving priority to certain 
compounds in specific seizure patterns and epilepsy syndromes.9,10 However, well 
designed and properly conducted randomized controlled trials are lacking, and some of the 
existing ones have significant methodologic problems. Therefore, selection of a specific 
antiepileptic drug is often influenced by a number of considerations, including mechanism 
of action, pharmacokinetics, patient gender and age, presence of comorbidities, and the 
familiarity of the treating physician with a specific antiepileptic drug.
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Zonisamide is a benzisoxazole derivative with a sulfonamide 
side chain (1,2-benzisoxazole-3-methanesulfonamide) and is 
structurally unrelated to other antiepileptic drugs (Figure 1). 
It has been available in Japan since 1989, in South Korea 
since 1992, in the US since 2000, and in the European Union 
since 2005. In the US, zonisamide is currently approved for 
the adjunctive treatment of partial seizures (with or without 
secondary generalization) in adults, while in Japan and 
Korea it is approved for both partial and generalized epilepsy 
in adults and children. In 2012, the European Medicine 
Agency issued marketing authorization approval to extend 
the use of zonisamide from adjunctive therapy to include 
monotherapy for partial seizures (with or without secondary 
generalization) in adults with newly diagnosed epilepsy. This 
review provides a comprehensive overview of zonisamide 
as monotherapy for partial seizures, with special attention 
to the possibility of a once-daily regimen. References were 
identified by searches of Medline and PubMed using the 
key words “zonisamide”, “epilepsy”, “partial seizures”, 
and “monotherapy”. The list of relevant articles was hand-
searched for additional publications (eg, book chapters or 
review papers) if relevant to the discussion.
Mechanism of action
Zonisamide demonstrates a wide range of mechanisms of 
action. Primarily, it modulates voltage-gated ion channels. 
Zonisamide prolongs the inactive state of sodium channels,11 
similar to carbamazepine, phenytoin, and lamotrigine,12 
thus reducing sustained high-frequency repetitive firing 
of sodium-dependent action potentials.13 At the same 
time, zonisamide inhibits low-threshold, T-type calcium 
currents,14 similarly to ethosuximide and valproate,12 thereby 
preventing the spread of seizure discharge between cells.15 
Zonisamide also modulates gamma aminobutyric acid and 
glutamatergic neurotransmission, potentiating the former 
and inhibiting the latter. This may be indirectly related 
to activity at voltage-gated channels, but seems also to 
be related to modulation of specific transporters, such as 
gamma aminobutyric acid transporter 1 and glutamate 
transporter 1.16
Finally, zonisamide appears to increase extracellular 
concentrations of dopamine and serotonin as well as 
increasing acetylcholine metabolism.17 It is currently unclear 
to what extent these mechanisms contribute to the antiseizure 
activity of zonisamide. The same applies to the weak carbonic 
anhydrase inhibitor properties.18
Pharmacokinetic profile
Zonisamide has a bioavailability of almost 100%.19 Single-
dose studies show that the time taken to reach peak plasma 
concentrations is 2–5 hours under fasting conditions and 
4–6 hours with food.20 Zonisamide is about 40% protein-
bound, with a volume of distribution of 1.27 L/kg.19 
Zonisamide preferentially accumulates in red blood cells,21 
with a red blood cell to plasma ratio of 8. This phenomenon, 
observed in general with the sulfonamide agents,22 seems 
to be irrelevant in terms of the final plasma half-life of 
zonisamide.21 For doses of 200–400 mg, zonisamide shows 
a linear relationship between dose and area under the curve 
(AUC).23 Above 800 mg, the pharmacokinetics become 
nonlinear, possibly due to saturation of red blood cells.12 
Zonisamide has a long plasma half-life (63–69 hours), with 
steady state achieved in about 14 days.23
Zonisamide is metabolized primarily in the liver, with 
subsequent elimination via the renal route. Approximately 
50% of zonisamide is metabolized by the cytochrome P450 
(CYP)3A4 isoenzyme, although CYP2C19 and CYP3A5 may 
also contribute.24 Polymorphisms in CYP2C19, but not 
in CYP3A4 or CYP3A5, can alter zonisamide clearance, 
although probably not to a degree requiring adjustment of 
dosing.25 Acetylation accounts for a further 20% of zonisamide 
metabolism.21 None of the metabolites of zonisamide appear 
to have anticonvulsant activity.26 Finally, the remaining 30% 
of unaltered zonisamide is excreted in the urine. The oral 
clearance of zonisamide is about 700 mL per hour, and renal 
clearance is relatively low at about 3.5 mL per minute.21 In 
subjects with renal impairment, renal clearance of single 
doses is positively correlated with creatinine clearance, and 
plasma AUC is increased by 35% in those with creatinine 
clearance , 20 mL per minute.19
In special populations, such as the elderly (.65 years), 
zonisamide shows no clinically significant pharmacokinetic 
differences.26 Moreover, there is no significant interaction 
between zonisamide and oral contraceptives, in particular 
ethinylestradiol and norethindrone.27
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Figure 1 Chemical structure of zonisamide.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
398
Mula
Drug Design, Development and Therapy 2013:7
A major advantage of the pharmacokinetics of zonisamide 
is its long half-life, which allows once-daily dosing. 
However, concomitant use of enzyme-inducing medications 
alters the clearance rate of zonisamide, reducing the plasma 
half-life to 27–38 hours.21
Efficacy in monotherapy studies
The efficacy of zonisamide as addon treatment in patients 
with partial seizures has been investigated in four pivotal, 
randomized, double-blind, placebo-controlled Phase III 
trials.28–31 At the moment, data on monotherapy are limited 
to two studies, comprising a randomized double-blind study32 
and a Phase III noninferiority trial.33
A 40-week, randomized, double-blind, monotherapy 
study comparing zonisamide 25, 100, and 300 mg/day32 
enrolled 169 patients with newly diagnosed epilepsy and 
complex partial seizures. Although no significant differences 
were observed between the dosing groups, a general trend 
towards a greater effect was observed in the 300 mg group, 
with more patients remaining seizure-free for $6 months 
(50.8%) as compared with those receiving 25 mg/day or 
100 mg/day (33.9% and 30.8%, respectively). The lack of 
difference in response rates over such a wide dose range 
of zonisamide is of interest in light of earlier data on drug-
refractory patients. In fact, all previous studies unanimously 
showed significant effects on median seizure rates and 
the number of patients showing a 50% seizure reduction 
compared with placebo in dose ranges of 300–600 mg/day, 
and a Cochrane review confirmed these findings.34 In general 
terms, patients in the early stages of epilepsy show high 
responsiveness to medical treatment compared with highly 
refractory patients undergoing addon treatment. Therefore, 
it is possible that doses of zonisamide as low as 50 mg and 
100 mg daily may be effective in monotherapy.
A multicenter, randomized, double-blind, Phase III 
noninferiority trial involving 583 patients aged 18–75 years 
compared zonisamide once daily (n = 282) with flexible 
dosing of controlled-release carbamazepine (n = 301).33 
After initiation of treatment (zonisamide 100 mg/day versus 
carbamazepine 200 mg/day) and uptitration (zonisamide to 
300 mg/day versus carbamazepine to 600 mg/day), the patients 
entered a 26–78-week flexible dosing period (zonisamide 
200–500 mg versus carbamazepine 400–1200 mg daily, 
according to response and tolerability). Once seizure-free for 
at least 26 weeks, the patients entered a 26-week maintenance 
phase. The primary endpoint was the proportion of patients 
in the per protocol population achieving seizure freedom for 
at least 26 weeks. Overall, 79.4% of the zonisamide-treated 
patients and 83.7% of the carbamazepine-treated patients 
remained seizure-free for at least 26 weeks (Figure 2). 
This trial is one of the few done according to International 
League Against Epilepsy guidance,10 which recommends that 
active-controlled trials have a duration of at least 48 weeks, 
no forced exit criteria, and information on the proportion 
of patients who remain seizure-free for at least 24 weeks 
as part of the efficacy assessment. A relative 20% margin 
is considered in the International League Against Epilepsy 
guidelines for noninferiority trials. In this study, zonisamide 
was noninferior to controlled-release carbamazepine, 
showing an adjusted absolute treatment difference of 4.5% 
(95% confidence interval [CI] 12.2–3.1), and a relative 
treatment difference of 5.4% (95% CI 14.7–3.7).
Safety in monotherapy studies
A pooled analysis of data from the four pivotal trials for 
zonisamide as addon therapy in patients with partial seizures 
shows treatment-emergent adverse events in about 77.9% 
of patients taking zonisamide versus 67.7% of those on 
placebo, with discontinuation rates of 19.3% and 8.6% 
respectively.35 Such adverse events were usually mild 
to moderate and generally related to the central nervous 
system (ie, somnolence, dizziness, depression, anorexia). 
Cognitive and psychiatric adverse events during treatment 
with zonisamide have been considered to be of concern.36,37 
However, they seem to develop in predisposed subjects36 
and careful patient selection reduces this problem.38 Serious 
adverse events show a similar incidence in patients taking 
zonisamide (4.8%) or placebo (4.6%).35
Zonisamide and carbamazepine had a very similar safety 
profile in the noninferiority monotherapy trial, except for 
the effect on body weight.33 In fact, the overall incidence 
of treatment-emergent adverse events was similar for 
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Figure 2 Seizure freedom rates by seizure type in a noninferiority trial comparing 
zonisamide with extended-release carbamazepine.33
Abbreviations: ZNS, zonisamide; CBZ-ER, carbamazepine extended-release.
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zonisamide (60%) and carbamazepine (62%), as was the 
incidence of treatment-related adverse events (36% and 
38%, respectively). In the majority of cases, adverse events 
were mild to moderate, with serious adverse events being 
rare in both groups (1% for zonisamide versus 2% for 
carbamazepine). The discontinuation rate due to adverse 
events was similar in both groups (11% for zonisamide 
versus 12% for carbamazepine) and, interestingly, the 
spectrum of adverse events was also similar, apart from 
decreased appetite (8% for zonisamide versus 2% for 
carbamazepine), dizziness (4% for zonisamide versus 8% for 
carbamazepine), and weight loss (7% for zonisamide versus 
0% for carbamazepine, see Figure 3).
Discussion
In general terms, all the data presented suggest that 
zonisamide is an effective and well tolerated treatment option 
for adult patients with focal epilepsy. Results of retention 
rate studies are currently available only for zonisamide as 
addon treatment, showing a two-year retention rate of about 
60%.39,40 However, zonisamide is one of the few antiepileptic 
drugs with a noninferiority trial performed according to 
International League Against Epilepsy guidance.10 The only 
other two studies done according to these criteria involve 
levetiracetam versus controlled-release carbamazepine41 
and pregabalin versus lamotrigine.42 The scarcity of such 
trials is indicative of the numerous methodologic problems 
associated with data regarding antiepileptic monotherapy. 
However, it is important to bear in mind that such trials, 
although providing clinically useful information, also have 
methodologic considerations that, if ignored, may affect 
their interpretation. Methodologic considerations include 
ensuring that the limits of noninferiority are properly defined, 
that additional evidence is provided to show that the active 
comparator is effective in the population studied, and that the 
assay system has adequate sensitivity to detect any difference 
between treatments. In the study by Baulac et al,33 as pointed 
out by the authors themselves, almost twice as many patients 
in the zonisamide group discontinued because of withdrawal 
of consent in the per protocol population.
The broad efficacy spectrum of zonisamide, due to its 
multiple mechanisms of action, represents an advantage, 
especially for patients without clearly classified seizures. In 
fact, zonisamide seems to be effective against both partial 
and primarily generalized seizures,43 making exacerbation 
of some generalized seizure types less likely than that found 
with carbamazepine.
The pharmacokinetic profile of zonisamide also has a 
number of advantages. First, the long half-life allows once-
daily dosing, improves patient compliance, and suggests a 
low impact of missed doses on seizure control. Second, the 
lack of inducing properties means a low potential for drug 
interactions and a low potential on hormones and probably 
on bone density, although data on the latter are still lacking. 
However, it has to be acknowledged that the long half-life 
may represent a limitation when a rapid onset of action is 
required.
Data on the adverse events of zonisamide in monotherapy 
are urgently needed. Data from addon studies are clearly not 
in favor of zonisamide, especially regarding adverse effects 
on cognition and behavior.36,44 However, preliminary data 
seem to suggest good tolerability.33 Such a discrepancy is 
frequently observed when the drug is used in monotherapy 
and individualized prescribing habits are adopted. Regarding 
adverse events, it has to be noted that zonisamide seems to be 
less problematic than other compounds (ie, carbamazepine 
and lamotrigine) in terms of idiosyncratic rash.
Finally, a peculiarity of zonisamide is weight loss, that 
seems to occur in about one third of treated patients, particu-
larly in those who were overweight before treatment.45 This 
effect seems to be more evident with zonisamide than with 
topiramate,46 another sulfamated antiepileptic drug, and may 
be particularly advantageous in some patients.
Conclusion
Zonisamide represents an effective and well tolerated option 
as monotherapy for adult patients with newly diagnosed focal 
epilepsy. Once-daily dosing is indicated in view of the long 
half-life and linear pharmacokinetics of this drug. The broad 
spectrum of efficacy in the treatment of different seizure types 
may be advantageous in seizure patterns that are not clearly 
classified. The low potential for drug interactions and the 
possibility of weight loss make zonisamide a preferred option 
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Figure 3 Treatment-emergent adverse events reported by $5% of patients in the 
noninferiority trial comparing zonisamide with extended-release carbamazepine.33
Abbreviations: ZNS, zonisamide; CBZ-ER, carbamazepine extended-release.
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in many epilepsy practices. Further data on monotherapy in 
special populations, such as women of childbearing potential, 
are needed.
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References
 1. de Boer HM, Mula M, Sander JW. The global burden and stigma of 
epilepsy. Epilepsy Behav. 2008;12:540–546.
 2. Pugliatti M, Beghi E, Forsgren L, Ekman M, Sobocki P. Estimating the 
cost of epilepsy in Europe: a review with economic modeling. Epilepsia. 
2007;48:2224–2233.
 3. Yoon D, Frick KD, Carr DA, Austin JK. Economic impact of epilepsy 
in the United States. Epilepsia. 2009;50:2186–2191.
 4. Engel J Jr. A proposed diagnostic scheme for people with epileptic 
seizures and with epilepsy: report of the ILAE Task Force on 
Classification and Terminology. Epilepsia. 2001;42:796–803.
 5. Berg AT, Shinnar S, Levy SR, Testa FM, Smith-Rapaport S, 
Beckerman B. How well can epilepsy syndromes be identified at 
diagnosis? A reassessment 2 years after initial diagnosis. Epilepsia. 
2000;41:1269–1275.
 6. Brodie MJ, Barry SJ, Bamagous GA, Norrie JD, Kwan P. Patterns of 
treatment response in newly diagnosed epilepsy. Neurology. 2012;78: 
1548–1554.
 7. Kwan P, Sander JW. The natural history of epilepsy: an epidemiological 
view. J Neurol Neurosurg Psychiatry. 2004;75:1376–1381.
 8. Noe KH. Seizures: diagnosis and management in the outpatient setting. 
Semin Neurol. 2011;31:54–64.
 9. French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the 
new antiepileptic drugs, I: treatment of new-onset epilepsy: report of the 
TTA and QSS Subcommittees of the American Academy of Neurology 
and the American Epilepsy Society. Epilepsia. 2004;45:401–409.
 10. Glauser T, Ben-Menachem E, Bourgeois B, et al. ILAE treatment 
guidelines: evidence-based analysis of antiepileptic drug efficacy 
and effectiveness as initial monotherapy for epileptic seizures and 
syndromes. Epilepsia. 2006;47:1094–1120.
 11. Schauf CL. Zonisamide enhances slow sodium inactivation in Myxicola. 
Brain Res. 1987;413:185–188.
 12. Schulze-Bonhage A. Zonisamide in the treatment of epilepsy. Expert 
Opin Pharmacother. 2010;11:115–126.
 13. Rock DM, Macdonald RL, Taylor CP. Blockade of sustained repetitive 
action potentials in cultured spinal cord neurons by zonisamide 
(AD 810, CI 912), a novel anticonvulsant. Epilepsy Res. 1989;3: 
138–143.
 14. Suzuki S, Kawakami K, Nishimura S, et al. Zonisamide blocks T-type 
calcium channel in cultured neurons of rat cerebral cortex. Epilepsy 
Res. 1992;12:21–27.
 15. Kito M, Maehara M, Watanabe K. Mechanisms of T-type calcium 
channel blockade by zonisamide. Seizure. 1996;5:115–119.
 16. Ueda Y, Doi T, Tokumaru J, Willmore LJ. Effect of zonisamide on 
molecular regulation of glutamate and GABA transporter proteins 
during epileptogenesis in rats with hippocampal seizures. Brain Res 
Mol Brain Res. 2003;116:1–6.
 17. Okada M, Kaneko S, Hirano T, et al. Effects of zonisamide on 
extracellular levels of monoamine and its metabolite, and on Ca2+ 
dependent dopamine release. Epilepsy Res. 1992;13:113–119.
 18. Masuda Y, Noguchi H, Karasawa T. Evidence against a significant 
implication of carbonic anhydrase inhibitory activity of zonisamide in 
its anticonvulsive effects. Arzneimittelforschung. 1994;44:267–269.
 19. Leppik IE. Zonisamide: chemistry, mechanism of action, and 
pharmacokinetics. Seizure. 2004;13 Suppl 1:S5–S9.
 20. Peters DH, Sorkin EM. Zonisamide. A review of its pharmacodynamic 
and pharmacokinetic properties, and therapeutic potential in epilepsy. 
Drugs. 1993;45:760–787.
 21. Sills G, Brodie M. Pharmacokinetics and drug interactions with 
zonisamide. Epilepsia. 2007;48:435–441.
 22. Matsumoto K, Miyazaki H, Fujii T, Amejima H, Furukawa H, 
Hashimoto M. Binding of sulfonamides to erythrocyte proteins and 
possible drug-drug interaction. Chem Pharm Bull (Tokyo). 1989;37: 
2807–2810.
 23. Kochak GM, Page JG, Buchanan RA, Peters R, Padgett CS. Steady-state 
pharmacokinetics of zonisamide, an antiepileptic agent for treatment 
of refractory complex partial seizures. J Clin Pharmacol. 1998;38: 
166–171.
 24. Kothare SV, Kaleyias J. Zonisamide: review of pharmacology, clinical 
efficacy, tolerability, and safety. Expert Opin Drug Metab Toxicol. 
2008;4:493–506.
 25. Okada Y, Seo T, Ishitsu T, et al. Population estimation regarding 
the effects of cytochrome P450 2C19 and 3A5 polymorphisms on 
zonisamide clearance. Ther Drug Monit. 2008;30:540–543.
 26. Brodie MJ, Ben-Menachem E, Chouette I, Giorgi L. Zonisamide: its 
pharmacology, efficacy and safety in clinical trials. Acta Neurol Scand 
Suppl. 2012;194:19–28.
 27. Griffith SG, Dai Y. Effect of zonisamide on the pharmacokinetics and 
pharmacodynamics of a combination ethinyl estradiol-norethindrone 
oral contraceptive in healthy women. Clin Ther. 2004;26:2056–2065.
 28. Schmidt D, Jacob R, Loiseau P, et al. Zonisamide for add-on treatment 
of refractory partial epilepsy: a European double-blind trial. Epilepsy 
Res. 1993;15:67–73.
 29. Faught E, Ayala R, Montouris GG, Leppik IE. Randomized controlled 
trial of zonisamide for the treatment of refractory partial-onset seizures. 
Neurology. 2001;57:1774–1779.
 30. Sackellares JC, Ramsay RE, Wilder BJ, Browne TR 3rd, 
 Shellenberger MK. Randomized, controlled clinical trial of  zonisamide 
as adjunctive treatment for refractory partial seizures. Epilepsia. 2004; 
45:610–617.
 31. Brodie MJ, Duncan R, Vespignani H, Solyom A, Bitenskyy V, Lucas C. 
Dose-dependent safety and efficacy of zonisamide: a randomized, 
double-blind, placebo-controlled study in patients with refractory partial 
seizures. Epilepsia. 2005;46:31–41.
 32. Naritoku D. Dose response efficacy of zonisamide monotherapy during 
40 weeks treatment of partial seizures in patients with newly diagnosed 
epilepsy. Epilepsia. 2006;47:138–139.
 33. Baulac M, Brodie MJ, Patten A, Segieth J, Giorgi L. Efficacy and 
tolerability of zonisamide versus controlled-release carbamazepine for 
newly diagnosed partial epilepsy: a phase 3, randomised, double-blind, 
non-inferiority trial. Lancet Neurol. 2012;11:579–588.
 34. Chadwick DW, Marson AG. Zonisamide add-on for drug-resistant partial 
epilepsy. Cochrane Database Syst Rev. 2005;4:CD001416.
 35. Brodie MJ. Zonisamide as adjunctive therapy for refractory partial 
seizures. Epilepsy Res. 2006;68 Suppl 2:S11–S16.
 36. Mula M, Sander JW. Negative effects of antiepileptic drugs on mood 
in patients with epilepsy. Drug Saf. 2007;30:555–567.
 37. Mula M, Monaco F. Antiepileptic drugs and psychopathology of 
epilepsy: an update. Epileptic Disord. 2009;11:1–9.
 38. Zaccara G, Tramacere L, Cincotta M. Drug safety evaluation of 
zonisamide for the treatment of epilepsy. Expert Opin Drug Saf. 
2011;10:623–631.
 39. Chung S, Wang N, Hank N. Comparative retention rates and long-term 
tolerability of new antiepileptic drugs. Seizure. 2007;16:296–304.
 40. Catarino CB, Bartolini E, Bell GS, Yuen AW, Duncan JS, Sander JW. 
The long-term retention of zonisamide in a large cohort of people with 
epilepsy at a tertiary referral centre. Epilepsy Res. 2011;96:39–44.
 41. Brodie MJ, Perucca E, Ryvlin P, Ben-Menachem E, Meencke HJ. 
Comparison of levetiracetam and controlled-release carbamazepine in 
newly diagnosed epilepsy. Neurology. 2007;68:402–408.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
401
Once-daily zonisamide for partial seizures in adults
Drug Design, Development and Therapy
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/drug-design-development-and-therapy-journal
Drug Design, Development and Therapy is an international, peer-
reviewed open-access journal that spans the spectrum of drug design 
and development through to clinical applications. Clinical outcomes, 
patient safety, and programs for the development and effective, safe, 
and sustained use of medicines are a feature of the journal, which 
has also been accepted for indexing on PubMed Central. The manu-
script management system is completely online and includes a very 
quick and fair peer-review system, which is all easy to use. Visit 
http://www.dovepress.com/testimonials.php to read real quotes from 
published authors.
Drug Design, Development and Therapy 2013:7
 42. Kwan P, Brodie MJ, Kalviainen R, Yurkewicz L, Weaver J, Knapp LE. 
Efficacy and safety of pregabalin versus lamotrigine in patients with 
newly diagnosed partial seizures: a phase 3, double-blind, randomised, 
parallel-group trial. Lancet Neurol. 2011;10:881–890.
 43. Marinas A, Villanueva V, Giraldez BG, Molins A, Salas-Puig J, 
Serratosa JM. Efficacy and tolerability of zonisamide in idiopathic 
generalized epilepsy. Epileptic Disord. 2009;11:61–66.
 44. Mula M, Trimble MR. Antiepileptic drug-induced cognitive adverse 
effects: potential mechanisms and contributing factors. CNS Drugs. 
2009;23:121–137.
 45. Wellmer J, Wellmer S, Bauer J. The impact of zonisamide on weight. 
A clinical study in 103 patients with epilepsy. Acta Neurol Scand. 
2009;119:233–238.
 46. Antel J, Hebebrand J. Weight-reducing side effects of the antiepileptic 
agents topiramate and zonisamide. Handb Exp Pharmacol. 2012;209: 
433–466.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
402
Mula
